<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892123</url>
  </required_header>
  <id_info>
    <org_study_id>ZWI-ZW25-101</org_study_id>
    <nct_id>NCT02892123</nct_id>
  </id_info>
  <brief_title>Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers</brief_title>
  <official_title>Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymeworks Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zymeworks Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, 3-part study to investigate the safety, tolerability, and&#xD;
      effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents&#xD;
      in patients with locally advanced (unresectable) and/or metastatic human epidermal growth&#xD;
      factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the&#xD;
      body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of the study will evaluate increasing doses of ZW25 to find the highest dose of ZW25&#xD;
      that does not cause unacceptable side effects (maximum-tolerated dose or MTD), the lowest&#xD;
      safe dose with the highest rate of effectiveness (optimal biological dose or OBD), and/or&#xD;
      other recommended dosages (RDs) of ZW25 in up to 7 dose-specific cohorts. Eligible patients&#xD;
      include those with selected HER2-expressing locally advanced (unresectable) and/or metastatic&#xD;
      cancers that have progressed after receipt of all therapies known to confer clinical benefit&#xD;
      (or ineligible to receive therapy).&#xD;
&#xD;
      Part 2 of the study will further evaluate the safety, tolerability, and efficacy of ZW25 in&#xD;
      patients with selected HER2-expressing locally advanced (unresectable) and/or metastatic&#xD;
      cancers that have progressed after receipt of all therapies known to confer clinical benefit&#xD;
      (or ineligible to receive therapy) in up to 5 separate disease-specific cohorts.&#xD;
&#xD;
      Part 3 of the study will evaluate the safety, tolerability, and efficacy of ZW25 combined&#xD;
      with selected chemotherapy agents, including paclitaxel, capecitabine, vinorelbine, or&#xD;
      capecitabine and tucatinib. Patients with selected HER2-expressing locally advanced&#xD;
      (unresectable) and/or metastatic cancers that have progressed after at least 1 and no more&#xD;
      than 3 prior systemic chemotherapy regimens will be evaluated in this part of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who experience dose-limiting toxicities (DLTs) (Part 1)</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Parts 2 and 3)</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ZW25</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who develop detectable anti-drug antibodies</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival as defined by RECIST 1.1 criteria</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Part 1)</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>HER2-expressing Cancers</condition>
  <arm_group>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZW25 (Zanidatamab)</intervention_name>
    <description>ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:</description>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4</description>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5</description>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6</description>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7</description>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)</description>
    <arm_group_label>ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HER2-expressing cancer as follows:&#xD;
&#xD;
             Part 1:&#xD;
&#xD;
               -  Cohorts 1 - 3: Any locally advanced (unresectable) and/or metastatic&#xD;
                  HER2-expressing (HER2 1+, 2+, or 3+ by IHC) cancer (including but not limited to&#xD;
                  breast, gastric, ovarian, colorectal and non-small cell lung) that has progressed&#xD;
                  after receipt of all therapies known to confer clinical benefit&#xD;
&#xD;
               -  Cohort 4:&#xD;
&#xD;
                    -  HER2 IHC 2+ /FISH- breast cancer or gastroesophageal adenocarcinoma (GEA)&#xD;
&#xD;
                    -  HER2 IHC 3+ or HER2 IHC 2+ /FISH+ breast cancer or GEA&#xD;
&#xD;
                    -  Any other HER2 IHC 3+ or FISH+ cancer&#xD;
&#xD;
                         -  HER2-overexpressing (3+ by IHC) or HER2-2+ and FISH+ breast cancer must&#xD;
                            have progressed after prior treatment with trastuzumab, pertuzumab, and&#xD;
                            T-DM1&#xD;
&#xD;
                         -  HER2-overexpressing (3+ by IHC) or HER2-2+ and FISH+ GEA must have&#xD;
                            progressed after prior treatment with trastuzumab&#xD;
&#xD;
                         -  Patients with colorectal cancer must be KRAS wild-type&#xD;
&#xD;
                         -  Patients with NSCLC must have ALK wild-type, EGFR wild-type, and ROS1&#xD;
                            fusion negative as determined by standard methods&#xD;
&#xD;
               -  Cohorts 5 - 6: HER2 IHC 3+ or HER2 IHC 2+ /FISH+ GEA must have progressed after&#xD;
                  prior treatment with trastuzumab&#xD;
&#xD;
               -  Cohort 7 (only at selected sites): HER2 IHC 3+, HER2 IHC 2+ /FISH+, or HER2 IHC&#xD;
                  2+ /FISH- breast cancer must have progressed after prior treatment with&#xD;
                  trastuzumab, pertuzumab, and T-DM1&#xD;
&#xD;
             Part 2:&#xD;
&#xD;
             Locally advanced (unresectable) and/or metastatic cancer that has progressed after&#xD;
             receipt of all therapies known to confer clinical benefit (unless ineligible to&#xD;
             receive a specific therapy) as follows:&#xD;
&#xD;
               -  Cohort 1: HER2 IHC 2+/FISH- breast cancer&#xD;
&#xD;
               -  Cohort 2: HER2 IHC 3+ or HER2 IHC 2+/FISH+ breast cancer&#xD;
&#xD;
               -  Cohort 3: HER2 IHC 2+/FISH- GEA&#xD;
&#xD;
               -  Cohort 4: HER2 IHC 3+ or HER2 IHC 2+/FISH+ GEA&#xD;
&#xD;
               -  Cohort 5: Any other HER2 IHC 3+ or IHC 2+/FISH+ cancer, including the following:&#xD;
&#xD;
                    -  Cohort 5a: HER2 IHC 3+ or IHC 2+/FISH+ GI cancers other than GEA (patients&#xD;
                       with colorectal cancer must be KRAS wild-type.)&#xD;
&#xD;
                    -  Cohort 5b: Any other HER2 IHC 3+ or IHC 2+/FISH+ solid tumor types that are&#xD;
                       not breast or GI cancers (patients with NSCLC must have ALK wild-type, EGFR&#xD;
                       wild-type, and ROS1 fusion negative as determined by standard methods;&#xD;
                       patients with ovarian cancers must be KRAS wild type.)&#xD;
&#xD;
             Part 3:&#xD;
&#xD;
             Locally advanced (unresectable) and/or metastatic cancer as follows:&#xD;
&#xD;
               -  HER2 IHC 1+ or IHC2+/FISH- breast cancer patients (TGs 1, 2, or 3) who have&#xD;
                  received at least 1 and no more than 3 prior systemic chemotherapy regimens&#xD;
&#xD;
               -  HER2 IHC 3+ or IHC 2+/FISH+ breast cancer patients (TGs 1, 2, or 3) who have&#xD;
                  received prior therapy with trastuzumab, pertuzumab, and T-DM1, at least 1 and no&#xD;
                  more than 3 prior systemic chemotherapy regimens&#xD;
&#xD;
               -  HER2 IHC 2+ or 3+ FISH+ or FISH- GEA patients (TGs 1 or 2) who have received at&#xD;
                  least 1 and no more than 3 prior systemic chemotherapy regimens&#xD;
&#xD;
               -  HER2 IHC 3+ or IHC 2+/FISH+ GEA patients who have received prior therapy with&#xD;
                  trastuzumab (TG4; ZW25 + paclitaxel)&#xD;
&#xD;
               -  HER2 IHC 3+, IHC 2+/FISH+ or otherwise HER2-positive per ASCO/CAP guidelines&#xD;
                  breast cancer patients who have received prior therapy with trastuzumab,&#xD;
                  pertuzumab, and T-DM1 (TG5; ZW25 + capecitabine)&#xD;
&#xD;
               -  HER2 IHC 3+, IHC 2+/FISH+ or otherwise HER2-positive per ASCO/CAP guidelines&#xD;
                  breast cancer patients (TG6) who have received prior therapy with trastuzumab,&#xD;
                  pertuzumab, and T-DM1&#xD;
&#xD;
               -  HER2 IHC 3+, IHC2+/FISH+, or otherwise HER2-positive per ASCO/CAP guidelines&#xD;
                  breast cancer patients (TG7) who have received prior therapy with trastuzumab,&#xD;
                  pertuzumab, and T-DM1&#xD;
&#xD;
               -  HER2 IHC 3+, IHC 2+/FISH+, or otherwise HER2-positive per ASCO/CAP guidelines&#xD;
                  breast cancer patients (TG8) who have received prior therapy with trastuzumab,&#xD;
                  pertuzumab, and T-DM1&#xD;
&#xD;
          2. ≥ 18 years of age&#xD;
&#xD;
          3. ECOG performance status of 0 or 1&#xD;
&#xD;
          4. Life expectancy of at least 3 months per the investigator's assessment.&#xD;
&#xD;
          5. Adequate organ function&#xD;
&#xD;
          6. Adequate cardiac left ventricular function, as defined by a LVEF &gt;/= institutional&#xD;
             standard of normal&#xD;
&#xD;
          7. For Part 1 Cohorts 1 - 3: evaluable disease (target or non-target lesions) per RECIST&#xD;
             version 1.1. For Part 1 Cohorts 4 - 7, and Parts 2 and 3: measurable disease (target&#xD;
             lesions) per RECIST version 1.1&#xD;
&#xD;
          8. Able to provide tumor sample (fresh or archived)&#xD;
&#xD;
          9. For Part 3 TGs 7 and 8 only - based on screening brain MRI, patients must have one of&#xD;
             the following:&#xD;
&#xD;
               -  No evidence of brain metastases&#xD;
&#xD;
               -  Untreated brain metastases not needing immediate local therapy. For patients with&#xD;
                  untreated CNS lesions &gt; 2.0 cm on screening contrast brain MRI, discussion with&#xD;
                  and approval from the medical monitor is required prior to enrollment&#xD;
&#xD;
               -  Previously treated brain metastases that are either stable since treatment or&#xD;
                  have progressed since prior local CNS therapy, provided there is no clinical&#xD;
                  indication for immediate re-treatment with local therapy in the opinion of the&#xD;
                  investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Experimental therapies within 4 weeks before first ZW25 dosing&#xD;
&#xD;
          2. Treatment with other cancer therapy not otherwise specified within 4 weeks before ZW25&#xD;
             dosing&#xD;
&#xD;
          3. Anthracyclines within 90 days before first ZW25 dosing or lifetime load exceeding 300&#xD;
             mg/m² adriamycin or equivalent&#xD;
&#xD;
          4. Trastuzumab, pertuzumab, lapatinib, or T-DM1 within 3 weeks before first ZW25 dosing&#xD;
&#xD;
          5. Patients in Part 3 TG4 must not have received prior taxanes&#xD;
&#xD;
          6. Patients in Part 3 TG5 must not have received prior capecitabine for metastatic&#xD;
             disease or received any prior fam-trastuzumab deruxtecan-nxki (DS-8201a)&#xD;
&#xD;
          7. With the exception of Part 3 TGs 7 and 8, untreated brain metastases (patients with&#xD;
             treated brain mets who are off steroids and are stable for at least 1 month at the&#xD;
             time of screening are eligible)&#xD;
&#xD;
          8. Pregnant or breast-feeding women&#xD;
&#xD;
          9. History of life-threatening hypersensitivity to monoclonal antibodies or to&#xD;
             recombinant proteins or excipients in drug formulation&#xD;
&#xD;
         10. Acute or chronic uncontrolled renal disease, pancreatitis or liver disease (with&#xD;
             exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver&#xD;
             metastases, or stable chronic liver disease per investigator assessment)&#xD;
&#xD;
         11. Peripheral neuropathy &gt; Grade 2&#xD;
&#xD;
         12. Clinically significant interstitial lung disease&#xD;
&#xD;
         13. Known active hepatitis B or C or known infection with HIV&#xD;
&#xD;
         14. Immunosuppressive corticosteroids equivalent to &gt; 15mg/day of prednisone within 2&#xD;
             weeks before first ZW25 dose&#xD;
&#xD;
         15. QTc Fridericia (QTcF) &gt; 450 ms&#xD;
&#xD;
         16. Having clinically significant cardiac disease such as ventricular arrhythmia requiring&#xD;
             therapy, uncontrolled hypertension or any history of symptomatic CHF&#xD;
&#xD;
         17. Having known myocardial infarction or unstable angina within 6 months before first&#xD;
             ZW25 dosing&#xD;
&#xD;
         18. Patients in Part 3 TG7 must not have received prior capecitabine or tucatinib for&#xD;
             metastatic disease&#xD;
&#xD;
         19. Patients in Part 3 TG8 must not have received prior tucatinib therapy for metastatic&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajen Oza, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Zymeworks Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zymeworks Clinical Trial Resource</last_name>
    <phone>(206) 237-1030</phone>
    <email>medinfo@zymeworks.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diana Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Family Cancer Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diana Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Mayordomo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melody Cobleigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muralidha Beeram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorge Chaves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel Goodwin, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Elimova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cristiano Ferrario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keun-Wook Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sun Young Rha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeeyun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Biparatopic antibody</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Gastroesophageal adenocarcinoma (GEA)</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastroesophageal junction (GEJ) cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Vinorelbine</keyword>
  <keyword>Tucatinib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

